Kales A, Soldatos C R, Bixler E O, Kales J D
Pharmacology. 1983;26(3):121-37. doi: 10.1159/000137794.
Rebound insomnia and rebound anxiety are clinical conditions related to withdrawal of certain benzodiazepine drugs. Numerous studies of benzodiazepine and nonbenzodiazepine hypnotics conducted in our sleep laboratory demonstrated that rebound insomnia developed following withdrawal from benzodiazepines with a rapid or intermediate elimination rate. Several studies conducted by other investigators also indicated the development of rebound insomnia under similar conditions. Rebound insomnia and rebound anxiety are discussed in terms of their interrelationship, clinical implications, and receptor mechanisms. Evidence suggests that drugs producing rebound insomnia and rebound anxiety also show a more rapid development of tolerance and greater potential for drug dependence than benzodiazepines where the parent compound or its metabolites have a long elimination half-life.
反弹性失眠和反弹性焦虑是与某些苯二氮䓬类药物戒断相关的临床病症。我们睡眠实验室对苯二氮䓬类和非苯二氮䓬类催眠药进行的大量研究表明,在快速或中等消除率的苯二氮䓬类药物戒断后会出现反弹性失眠。其他研究人员进行的几项研究也表明在类似情况下会出现反弹性失眠。本文从它们的相互关系、临床意义和受体机制方面对反弹性失眠和反弹性焦虑进行了讨论。有证据表明,与母体化合物或其代谢物具有较长消除半衰期的苯二氮䓬类药物相比,导致反弹性失眠和反弹性焦虑的药物也表现出更快的耐受性发展和更大的药物依赖潜力。